BioSpace News Archive

TG Therapeutics, Inc., announced that a conference call will be held on Wednesday, February 28, 2024, at 8:30 AM ET to discuss results for the fourth quarter and year-end 2023 and provide a business outlook for 2024.

SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”) today announced Samuel J. Reich, the Company’s Chairman and CEO, will present an overview of the Company at the BIO CEO & Investor Conference on Monday, February 26, 2024 at 3:15 PM EST.

Gamida Cell Ltd. presented data highlighting its expanded access program for FDA-approved allogeneic stem cell therapy Omisirge® and Phase 1 data for its allogeneic cryopreserved natural killer cell therapy candidate GDA-201 at the 2024 Tandem Meetings, Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research.

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper) is presenting results from three preclinical studies evaluating briquilimab, at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, being held February 23-26 in Washington, D.C.

Oscotec Inc. and ADEL Inc. announced the dosing of the first healthy participant in its first-in-human study of ADEL-Y01 for the treatment of Alzheimer’s disease (AD).

Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”) today announced that George Magrath, M.D. M.B.A, M.S. CEO of Ocuphire, will be presenting a company overview at the BIO CEO & Investor Conference being held February 26-27 2024 in New York City.

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company has obtained prequalification certification from the World Health Organization for its typhoid conjugate vaccine, ‘SKYTyphoid®'.

Vir Biotechnology, Inc. announced that management will be participating in the following upcoming investor conferences during the month of March: TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place in Boston.

Venatorx Pharmaceuticals (Venatorx) and Melinta Therapeutics (Melinta) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for cefepime-taniborbactam.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two upcoming investor conferences.